• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接近种系的人源单克隆抗体可中和并预防多种致关节炎的甲病毒。

Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.

机构信息

Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461.

Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110.

出版信息

Proc Natl Acad Sci U S A. 2021 Sep 14;118(37). doi: 10.1073/pnas.2100104118.

DOI:10.1073/pnas.2100104118
PMID:34507983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8449321/
Abstract

Arthritogenic alphaviruses are globally distributed, mosquito-transmitted viruses that cause rheumatological disease in humans and include Chikungunya virus (CHIKV), Mayaro virus (MAYV), and others. Although serological evidence suggests that some antibody-mediated heterologous immunity may be afforded by alphavirus infection, the extent to which broadly neutralizing antibodies that protect against multiple arthritogenic alphaviruses are elicited during natural infection remains unknown. Here, we describe the isolation and characterization of MAYV-reactive alphavirus monoclonal antibodies (mAbs) from a CHIKV-convalescent donor. We characterized 33 human mAbs that cross-reacted with CHIKV and MAYV and engaged multiple epitopes on the E1 and E2 glycoproteins. We identified five mAbs that target distinct regions of the B domain of E2 and potently neutralize multiple alphaviruses with differential breadth of inhibition. These broadly neutralizing mAbs (bNAbs) contain few somatic mutations and inferred germline-revertants retained neutralizing capacity. Two bNAbs, DC2.M16 and DC2.M357, protected against both CHIKV- and MAYV-induced musculoskeletal disease in mice. These findings enhance our understanding of the cross-reactive and cross-protective antibody response to human alphavirus infections.

摘要

关节炎相关的甲病毒在全球范围内广泛分布,通过蚊子传播,可导致人类发生风湿性疾病,包括基孔肯雅热病毒(CHIKV)、马亚罗病毒(MAYV)等。虽然血清学证据表明,甲病毒感染可能会提供一些抗体介导的异源免疫,但在自然感染过程中,广泛中和抗体(可预防多种关节炎相关甲病毒)的产生程度仍不清楚。在此,我们描述了从 CHIKV 恢复期供体中分离和鉴定 MAYV 反应性甲病毒单克隆抗体(mAb)的情况。我们鉴定了 33 种与人 CHIKV 和 MAYV 发生交叉反应的人类 mAb,这些 mAb 可与 E1 和 E2 糖蛋白上的多个表位结合。我们鉴定了 5 种靶向 E2 蛋白 B 结构域不同区域的 mAb,这些 mAb 可强力中和多种甲病毒,且抑制范围存在差异。这些广泛中和 mAb(bNAb)含有较少的体细胞突变,推断的种系回复突变体保留了中和能力。两种 bNAb,DC2.M16 和 DC2.M357,可预防 CHIKV 和 MAYV 诱导的小鼠肌肉骨骼疾病。这些发现增强了我们对人类甲病毒感染的交叉反应和交叉保护抗体反应的理解。

相似文献

1
Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.接近种系的人源单克隆抗体可中和并预防多种致关节炎的甲病毒。
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37). doi: 10.1073/pnas.2100104118.
2
Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope.泛保护性抗甲病毒人抗体针对一个保守的 E1 蛋白表位。
Cell. 2021 Aug 19;184(17):4414-4429.e19. doi: 10.1016/j.cell.2021.07.006.
3
Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.基孔肯雅病毒暴露可部分交叉保护小鼠免受马亚罗病毒感染。
J Virol. 2021 Nov 9;95(23):e0112221. doi: 10.1128/JVI.01122-21. Epub 2021 Sep 22.
4
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.基孔肯雅病毒包膜三聚体外侧表位残基的暴露决定抗体中和效力。
J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.
5
Human mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing Conserved Elements of the Mxra8 Receptor-Binding Site.人源单抗通过识别 Mxra8 受体结合位点的保守元件广泛保护抗关节炎甲病毒。
Cell Host Microbe. 2020 Nov 11;28(5):699-711.e7. doi: 10.1016/j.chom.2020.07.008. Epub 2020 Aug 11.
6
Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.广谱中和性甲病毒抗体结合 E2 上的一个表位,并抑制进入和离开。
Cell. 2015 Nov 19;163(5):1095-1107. doi: 10.1016/j.cell.2015.10.050. Epub 2015 Nov 6.
7
Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.腺病毒载体型马亚罗病毒和基孔肯雅病毒候选疫苗可在 A129 小鼠模型中提供针对致死性挑战的部分交叉保护。
Front Immunol. 2020 Nov 4;11:591885. doi: 10.3389/fimmu.2020.591885. eCollection 2020.
8
Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.抗基孔肯雅病毒的人源单克隆抗体针对 E1 和 E2 糖蛋白中的多个不同表位。
PLoS Pathog. 2019 Nov 7;15(11):e1008061. doi: 10.1371/journal.ppat.1008061. eCollection 2019 Nov.
9
The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies.非中和性抗甲病毒抗体保护作用的机制基础。
Cell Rep. 2021 Apr 6;35(1):108962. doi: 10.1016/j.celrep.2021.108962.
10
Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses.基于非复制性腺病毒的马亚罗病毒疫苗可引发保护性免疫反应,并对其他甲病毒产生交叉保护作用。
PLoS Negl Trop Dis. 2021 Apr 1;15(4):e0009308. doi: 10.1371/journal.pntd.0009308. eCollection 2021 Apr.

引用本文的文献

1
Identification and Characterization of Antiviral Activity of Synthetic Compounds Against Mayaro Virus.合成化合物对马亚罗病毒抗病毒活性的鉴定与表征
Pharmaceuticals (Basel). 2025 May 13;18(5):717. doi: 10.3390/ph18050717.
2
Highly Potent Neutralizing Nanobodies Acting Against Chikungunya Virus Infection via Inhibiting Multiple Stages of the Viral Life Cycle.通过抑制基孔肯雅病毒生命周期的多个阶段来对抗基孔肯雅病毒感染的高效中和纳米抗体
Int J Mol Sci. 2025 Apr 23;26(9):3982. doi: 10.3390/ijms26093982.
3
Chikungunya virus and other emerging arthritogenic alphaviruses.基孔肯雅病毒及其他新出现的致关节炎甲病毒
Nat Rev Microbiol. 2025 May 7. doi: 10.1038/s41579-025-01177-8.
4
Deep mutationally scanned CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies.深度突变扫描的基孔肯雅病毒E3/E2病毒文库绘制了病毒氨基酸偏好图谱,并预测了中和基孔肯雅病毒抗体的病毒逃逸突变体。
J Virol. 2025 Apr 15;99(4):e0008125. doi: 10.1128/jvi.00081-25. Epub 2025 Mar 27.
5
The alphavirus determinants of intercellular long extension formation.细胞间长延伸形成的甲病毒决定因素。
mBio. 2025 Feb 5;16(2):e0198624. doi: 10.1128/mbio.01986-24. Epub 2024 Dec 19.
6
Deep mutationally scanned (DMS) CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies.深度突变扫描(DMS)的基孔肯雅病毒E3/E2病毒文库绘制了病毒氨基酸偏好图谱,并预测了中和基孔肯雅病毒抗体的病毒逃逸突变体。
bioRxiv. 2024 Dec 4:2024.12.04.626854. doi: 10.1101/2024.12.04.626854.
7
Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.基孔肯雅病毒E2 B结构域纳米颗粒免疫原在小鼠体内引发同型中和抗体。
Vaccine. 2024 Dec 2;42(26):126405. doi: 10.1016/j.vaccine.2024.126405. Epub 2024 Oct 15.
8
Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection.基孔肯雅病毒和马亚罗病毒疫苗诱导的保护作用中的非互惠性。
Vaccines (Basel). 2024 Aug 27;12(9):970. doi: 10.3390/vaccines12090970.
9
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.经批准的减毒活基孔肯雅病毒疫苗(IXCHIQ)引发的交叉中和抗体广度扩展至多种致关节炎甲病毒,类似于自然感染后的抗体广度。
Vaccines (Basel). 2024 Aug 7;12(8):893. doi: 10.3390/vaccines12080893.
10
Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase.同时靶向流感病毒血凝素和神经氨酸酶的具有广泛保护作用的双特异性抗体。
mBio. 2024 Jul 17;15(7):e0108524. doi: 10.1128/mbio.01085-24. Epub 2024 Jun 20.

本文引用的文献

1
The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies.非中和性抗甲病毒抗体保护作用的机制基础。
Cell Rep. 2021 Apr 6;35(1):108962. doi: 10.1016/j.celrep.2021.108962.
2
Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.腺病毒载体型马亚罗病毒和基孔肯雅病毒候选疫苗可在 A129 小鼠模型中提供针对致死性挑战的部分交叉保护。
Front Immunol. 2020 Nov 4;11:591885. doi: 10.3389/fimmu.2020.591885. eCollection 2020.
3
Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses.致关节炎的甲病毒:新兴虫媒病毒的流行病学和临床视角。
Lancet Infect Dis. 2021 May;21(5):e123-e133. doi: 10.1016/S1473-3099(20)30491-6. Epub 2020 Nov 5.
4
A molecular understanding of alphavirus entry.甲病毒进入的分子机制研究
PLoS Pathog. 2020 Oct 22;16(10):e1008876. doi: 10.1371/journal.ppat.1008876. eCollection 2020 Oct.
5
Structural basis of Chikungunya virus inhibition by monoclonal antibodies.基孔肯雅病毒抑制的结构基础:单克隆抗体的作用。
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27637-27645. doi: 10.1073/pnas.2008051117. Epub 2020 Oct 21.
6
Mayaro Virus Pathogenesis and Transmission Mechanisms.马亚罗病毒的发病机制与传播机制
Pathogens. 2020 Sep 8;9(9):738. doi: 10.3390/pathogens9090738.
7
Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation.鉴定和结构的多供体类头导向流感中和抗体揭示其经常引发的机制。
Cell Rep. 2020 Sep 1;32(9):108088. doi: 10.1016/j.celrep.2020.108088.
8
Human mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing Conserved Elements of the Mxra8 Receptor-Binding Site.人源单抗通过识别 Mxra8 受体结合位点的保守元件广泛保护抗关节炎甲病毒。
Cell Host Microbe. 2020 Nov 11;28(5):699-711.e7. doi: 10.1016/j.chom.2020.07.008. Epub 2020 Aug 11.
9
A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice.一种交叉反应性抗体可预防罗斯河病毒肌肉骨骼疾病,尽管在小鼠中迅速发生中和逃逸。
PLoS Pathog. 2020 Aug 6;16(8):e1008743. doi: 10.1371/journal.ppat.1008743. eCollection 2020 Aug.
10
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.从 COVID-19 患者中分离出具有强大接近种系 SARS-CoV-2 中和抗体的纵向研究。
Cell. 2020 Aug 20;182(4):843-854.e12. doi: 10.1016/j.cell.2020.06.044. Epub 2020 Jul 13.